Supplementary Figure S4 from FDA Approval Summary: Axatilimab for Adult and Pediatric Patients Weighing at Least 40 Kilograms with Chronic GVHD after Two Prior Lines of Systemic Therapy | Synapse
September 10, 2025Open Access
Supplementary Figure S4 from FDA Approval Summary: Axatilimab for Adult and Pediatric Patients Weighing at Least 40 Kilograms with Chronic GVHD after Two Prior Lines of Systemic Therapy
Puntos clave
The analysis illustrates time to adverse events of special interest (AESIs) with axatilimab treatment in chronic GVHD.
Findings indicate that chronic GVHD patients, after two prior lines of systemic therapy, benefit from receiving axatilimab for improved management.
The data includes both adult and pediatric patient outcomes, providing a comprehensive view of treatment effectiveness.
Understanding these timeframes may guide future therapeutic decisions for patients struggling with chronic GVHD.